^
    Back
    Association details:
    Biomarker:Chr t(11;14) + BCL2 overexpression
    Cancer:Multiple Myeloma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Darzalex (daratumumab) (CD38 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Int J Mol Sci
    Title:

    Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma

    Published date:
    10/05/2021
    Excerpt:
    Here, we treated the MM cell lines KMS12PE and KMS27 with a combination treatment of venetoclax targeting BCL-2 and daratumumab targeting CD38 to evaluate the synergistic cytotoxicity of these drugs in vitro...results indicated that the antibody-dependent cell-mediated NK cytotoxicity was enhanced in KMS12PE and KMS27 cells harboring t(11;14) with a high BCL-2 expression suggesting that the combination treatment of venetoclax and daratumumab should be especially effective in patients with these characteristics.
    DOI:
    10.3390/ijms221910761
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    Synergistic Effect of Venetoclax for Antibody Dependent Cell Cytotoxicity By Daratumumab

    Published date:
    11/04/2020
    Excerpt:
    Collectively, these results indicate that the antibody-dependent cell-mediated cytotoxicity was enhanced in KMS12PE cells harboring t (11;14) with high BCL2 expression, suggesting that the combination of venetoclax and daratumumab displays a synergistic effect in treating MM harboring t (11;14) with high BCL2 expression.